Test Price
2,000 AED✅ Home Collection Available
Prenatal Hemophilia A Common Mutation Screening (Factor VIII Intron 22 & Intron 1 Inversion Analysis) in UAE | 2000 AED | 2026 DHA Guidelines
Lab facility licensed by DHA/MOHAP | ISO 9001:2015 Certified
تحليل فحص الطفرات الشائعة للهيموفيليا أ قبل الولادة (انقلاب الإنترون 22 والإنترون 1 لعامل التخثر الثامن) في الإمارات | 2000 درهم | معتمد من هيئة الصحة بدبي
Clinical Excellence & Patient Trust
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection; VIP Mobile Phlebotomy available 8 AM – 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
- ضمان الجودة: معالجة مخبرية بدقة 99.9% وفق معايير الآيزو، استشارة سريرية بعد الفحص، ودعم تأميني عبر واتساب.
Test Overview
The Prenatal Hemophilia A Common Mutation Screening test detects the most frequent causative inversions in the F8 gene (Intron 22 and Intron 1) using endpoint PCR, providing accurate carrier and fetal status. This non-invasive screening (on maternal blood or invasive sample) is essential for families with a history of Hemophilia A, guided by OB/GYN and hematology specialists.
| Feature | Our Test (Endpoint PCR) | Closest Alternative (NGS Panel) |
|---|---|---|
| Precision | Targeted detection of common inversions (Intron 22 & Intron 1) with 99.9% sensitivity | Broad screen but may miss large inversions without long-read technology |
| Method | Multiplex Endpoint PCR (Gold Standard for inversions) | Next-Generation Sequencing (capture-based) |
| Speed | TAT: 10–11 days, focused and rapid | TAT: 14–21 days, complex bioinformatics |
| Clinical Yield | Covers ~45% of severe Hemophilia A mutations | Covers point mutations but may miss inversions |
Physician Insight & Safety Protocol
“As a DHA-licensed clinical pathologist, I emphasize that this test provides crucial prenatal genetic information but must be interpreted in conjunction with comprehensive genetic counseling and family history. A negative result does not exclude other rare F8 mutations; thus, clinical correlation with coagulation factor assays is always advised.” – Dr. PRABHAKAR REDDY, DHA License: 61713011.
⚠️ Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This genetic screening does not replace medical management of bleeding disorders.
Exclusion Criteria & Emergency Red Flags
- Test not recommended for minors without parental consent and genetic counseling per UAE CDS Law 2026.
- Invasive sampling (amniotic fluid, CVS) carries a small risk of miscarriage; alternative non-invasive prenatal testing (NIPT) for maternal blood may be discussed.
- If you experience severe abdominal pain, heavy vaginal bleeding, or fever after invasive procedure, seek emergency care immediately.
- Results must be disclosed by a qualified healthcare professional; self-interpretation is clinically unsafe.
Patient FAQ & Clinical Guidance
What is the purpose of prenatal Factor VIII inversion screening?
This detects the two most common genetic inversions (Intron 22 and Intron 1) in the F8 gene causing severe Hemophilia A, enabling early prenatal diagnosis for at-risk pregnancies. It is typically requested when a pregnant woman is a known carrier or has a family history of hemophilia A, and can be performed on chorionic villus sampling or amniotic fluid from 11 weeks gestation.
ما هي الفترة الزمنية المثلى لإجراء هذا الفحص قبل الولادة؟
يمكن إجراء الفحص باستخدام عينة من الزغابات المشيمية بين الأسبوع 11 و13 من الحمل أو السائل الأمنيوسي بعد الأسبوع 15، مما يمنح وقتًا كافيًا لاتخاذ القرارات السريرية. يُفضَّل التنسيق مع طبيب النساء والولادة وفرع الوراثة الطبية لضمان سير الإجراء في الوقت المناسب.
How should I prepare for the sample collection, and are there any medication restrictions?
No fasting or special preparation is needed for maternal blood draw; however, for invasive prenatal sampling, your doctor will give specific instructions to minimize risks. Continue all prescribed medications unless your physician advises otherwise. Inform the phlebotomist of any blood thinners or clotting factor concentrates you are receiving.
DHA/MOHAP Facility License: 9834453 | ISO 9001:2015 Certified (Cert: INT/EGQ/2509DA/3139). Support & Booking: +971 54 548 8731 (WhatsApp).
This information is for educational purposes and does not replace professional medical advice.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians